Testing specimens for Chlamydia trachomatis

Genotyping of Chlamydia trachomatis from endocervical specimens in Shiraz, Iran

The objective of this study was to determine the prevalence and distribution of Chlamydia trachomatisgenotypes in Shiraz, Iran. Two hundred twelve cervical swab samples were collected from women attendingShahid Motahari Polyclinic in Shiraz, Iran. The endocervical specimens were screened for C. trachomatis byplasmid PCR. Genotyping was performed in C. trachomatis-positive samples by nested PCR ...

Chlamydia trachomatis: Molecular Testing Methods

Screening tests to detect Chlamydia trachomatis infections have advanced to permit the detection of nucleic acids from organisms. The development of these molecular assays that can detect and amplify the specific nucleic acids from the genes of C. trachomatis are called nucleic acid amplification tests (NAATs) and they have expanded the range of available specimen types to include noninvasive s...

Testing for Chlamydia trachomatis and Neisseria gonorrhoeae

Laboratory testing for Chlamydia trachomatis urogenital infections.

This review focuses on the laboratory diagnosis of Chlamydia trachomatis urogenital infections in adult patients. Laboratory diagnoses of C. trachomatis have rapidly evolved over the last two decades. The evolution from culture to enzyme immunoassay to nucleic acid amplification assay was a big step in the advance in technology. This advance has helped to improve the diagnosis and prevention of...

Inhibition of PCR in genital and urine specimens submitted for Chlamydia trachomatis testing.

We determined the frequency of PCR inhibition in genital and urine specimens submitted for Chlamydia trachomatis testing using the internal control DNA provided with the COBAS AMPLICOR C. trachomatis test and assessed methods to remove it. Inhibition occurred in 65 of 906 (7%) cervical swabs, 23 of 51 (45%) urethral swabs, and 2 of 175 (1.1%) urine samples. Overall, inhibition was eliminated in...